Evaluation of the effectiveness of plasmapheresis treatment in comparison with standard treatment in improving the symptoms of high-risk patients

Ghoum University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2020年10月6日

试验速览

暂无简介。

•Adults (defined) as older than 18 years and younger than 60 years
•Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from oropharyngeal or nasopharyngeal swab
•Covid19-related new organ dysfunction, including hypoxia due to the need for supplemental oxygen to maintain oxygen saturation greater than 94%, hypotension (systolic blood pressure less than 90 mm Hg) or the need for vasopressor, an inotropic drug ( Renal impairment (increase in creatinine by more than 50% from baseline, decrease in glomerular filtration rate by more than 25% from onset or urination less than 0.5 ml / kg for 6 hours, decrease in Glasgow scale by 2 or more, ie 13 or less Out of 15 points, thrombocytopenia less than 150,000 platelets per millimeter, gastrointestinal symptoms requiring hospitalization (eg severe nausea, vomiting, diarrhea or abdominal pain)

•Sensitivity or sensitivity to Lopinavir or Ritonavir or recombinant IFN-ß1b, including, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome.
•Use of drugs that are contraindicated with lopinavir/ritonavir and should not be substituted or discontinued during the study period, such as inhibitors CYP3A
•Pregnancy-Eligible female participants of childbearing age are tested for pregnancy before enrolling in the study
•HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs.
•Hemoglobin under 8
•Known heart failure EF under 50%
•According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or prisoners, are excluded from the study.

发起方

Ghoum University of Medical Sciences